Non-small cell lung cancer (NSCLC) accounts for one in five of all cancer deaths worldwide. Most patients are diagnosed at advanced stages, resulting in a 5-year survival rate of less than 20%. Recently, immune checkpoint inhibitors (ICIs) for PD-L1 and PD-1 have received FDA approval for the treatment of NSCLC. However, only a small subset of patients (15-20%) respond to ICIs, and many of these responders eventually relapse. Doxorubicin (DOX) is an FDA-approved chemotherapeutic used in treating many cancers, including lung cancer. However, it has dose-dependent toxicity and patients develop resistance to DOX over time.
Details
Title
Nanoparticles co-delivering doxorubicin & pd-l1 inhibitor to induce immunogenic cell death and enhance anti-cancer immune response in lung cancer
Creator
Kumar, Pramod : Oregon Health and Science University Wallstrum, Alyssa : Oregon Health and Science University Reda, Moataz : Oregon Health and Science University Wang, Ruijie : Oregon Health and Science University Ngamcherdtrakul, Worapol : Oregon Health and Science University Yantasee, Wassana : Oregon Health and Science University
Meeting Name
Research Week, Oregon Health and Science University, 2024
